De novo synthesize of bile acids in pulmonary arterial hypertension lung

Metabolomics

Volumn 10, Issue 6, 2014, Pages 1169-1175

  Zhao, Yidan D ^a,b   Yun, Hana Z H ^a   Peng, Jenny ^a   Yin, Li ^a   Chu, Lei ^a   Wu, Licun ^a   Michalek, Ryan ^c   Liu, Mingyao ^a   Keshavjee, Shaf ^a   Waddell, Thomas ^a   Granton, John ^d   de Perrot, Marc ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MaRS Centre   (Canada)

^c METABOLON INC   (United States)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Bile acid pathway; Lung; Pulmonary arterial hypertension

Indexed keywords

EID: 84939885107     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-014-0653-y     Document Type: Article

References (24)

1. Archer, S. L., Weir, E. K., & Wilkins, M. R. (2010). Basic science of pulmonary arterial hypertension for clinicians: New concepts and experimental therapies. Circulation,121, 2045–2066.
2. Blondeau, K., Mertens, V., Vanaudenaerde, B. A., Verleden, G. M., Van Raemdonck, D. E., et al. (2009). Nocturnal weakly acidic reflux promotes aspiration of bile acids in lung transplant recipients. The Journal of Heart and Lung Transplantation,28, 141–148.
3. Bogaard, H. J., Al Husseini, A., Farkas, L., Farkas, D., Gomez-Arroyo, J., et al. (2012). Severe pulmonary hypertension: The role of metabolic and endocrine disorders. Pulmonary Circulation,2, 148–154.
4. Chen, Z., Lu, W., Garcia-Prieto, C., & Huang, P. (2007). The Warburg effect and its cancer therapeutic implications. Journal of Bioenergetics and Biomembranes,39, 267–274.
5. Cohen, J. C., Cali, J. J., Jelinek, D. F., Mehrabian, M., Sparkes, R. S., et al. (1992). Cloning of the human cholesterol 7 alpha-hydroxylase gene (CYP7) and localization to chromosome 8q11-q12. Genomics,14, 153–161.
6. Crestani, M., Galli, G., & Chiang, J. Y. (1993). Genomic cloning, sequencing, and analysis of the hamster cholesterol 7 alpha-hydroxylase gene (CYP7). Archives of Biochemistry and Biophysics,306, 451–460.
7. D’Ovidio, F., Mura, M., Tsang, M., Waddell, T. K., Hutcheon, M. A., et al. (2005). Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. The Journal of Thoracic and Cardiovascular Surgery,129, 1144–1152.
8. Evans, R., Haiber, S., Nilsson, M., & Morris, G. A. (2009). Isomer resolution by micelle-assisted diffusion-ordered spectroscopy. Analytical Chemistry,81, 4548–4550.
9. Fessel, J. P., Hamid, R., Wittmann, B. M., Robinson, L. J., Blackwell, T., et al. (2012). Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Pulmonary Circulation,2, 201–213.
10. Fujiwara, M., Yagi, H., Matsuoka, R., Akimoto, K., Furutani, M., et al. (2008). Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Circulation Journal,72, 127–133.
11. Hansmann, G., Wagner, R. A., Schellong, S., Perez, V. A., Urashima, T., et al. (2007). Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation,115, 1275–1284.
12. International PPHC, Lane, K. B., Machado, R. D., Pauciulo, M. W., Thomson, J. R., et al. (2000). Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nature Genetics,26, 81–84.
13. Hassoun PM MMea, Barnett CF et al., (2013) 5th World Symposium of Pulmonary Hypertension, Nice.
14. Nasim, M. T., Ogo, T., Ahmed, M., Randall, R., Chowdhury, H. M., et al. (2011). Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Human Mutation,32, 1385–1389.
15. Nishimoto, M., Noshiro, M., & Okuda, K. (1993). Structure of the gene encoding human liver cholesterol 7 alpha-hydroxylase. Biochimica et Biophysica Acta,1172, 147–150.
16. Olschewski, A. (2010). Targeting TASK-1 channels as a therapeutic approach. Advances in Experimental Medicine and Biology,661, 459–473.
17. Pugh, M. E., Robbins, I. M., Rice, T. W., West, J., Newman, J. H., et al. (2011). Unrecognized glucose intolerance is common in pulmonary arterial hypertension. The Journal of Heart and Lung Transplantation,30, 904–911.
18. Reitman, Z. J., Jin, G., Karoly, E. D., Spasojevic, I., Yang, J., et al. (2011). Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proceedings of the National Academy of Sciences,108, 3270–3275.
19. Stacher, E., Graham, B. B., Hunt, J. M., Gandjeva, A., Groshong, S. D., et al. (2012). Modern age pathology of pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine,186, 261–272.
20. Sutendra, G., Bonnet, S., Rochefort, G., Haromy, A., Folmes, K. D., et al. (2010). Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Science Translational Medicine,2, 44ra58.
21. Wang, D. P., & Chiang, J. Y. (1994). Structure and nucleotide sequences of the human cholesterol 7 alpha-hydroxylase gene (CYP7). Genomics,20, 320–323.
22. Xu, R. H., Pelicano, H., Zhou, Y., Carew, J. S., Feng, L., et al. (2005). Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Research,65, 613–621.
23. Zhao, Y. Y., Liu, Y., Stan, R. V., Fan, L., Gu, Y., et al. (2002). Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proceedings of the National Academy of Sciences,99, 11375–11380.
24. Zhao, Y., Peng, J., Lu, C., Hsin, M., Mura, M., et al. (2014). Metabolomic heterogeneity of pulmonary arterial hypertension. PLoS ONE,9, e88727.